分化型甲状腺癌<sup>131</sup>I治疗的现状

张洁; 石洪成

doi:10.3760/cma.j.issn.1673-4114.2009.03.009

分化型甲状腺癌¹³¹I治疗的现状

张洁 , 石洪成

文章导航 > 国际放射医学核医学杂志 > 2009, 33 > 3: (163-167)

引用本文:

Citation:

分化型甲状腺癌¹³¹I治疗的现状

张洁,
石洪成^,

复旦大学附属中山医院核医学科, 上海 200032

通讯作者: 石洪成, shihongcheng@sina.com

The status of postoperative therapy using iodine-131 in differentiated thyroid carcinoma

ZHANG Jie,
SHI Hong-cheng^,

Department of Nuclear Medicine, Zhongshan Hospital, Shanghai Fudan University, Shanghai 200032, China

Corresponding author: SHI Hong-cheng, shihongcheng@sina.com

摘要: 分化型甲状腺癌的系统治疗包括手术切除、¹³¹I治疗、促甲状腺激素(TSH)抑制治疗。¹³¹I治疗的有效性得到普遍认可,但在治疗过程中还有很多问题存有争议。
- 甲状腺肿瘤 /
- 碘放射性同位素 /
- 近距离放射疗法
Abstract: The systemic treatment of differentiated thyroid carcinoma include thyroidectomy, radioactive iodine and thyroxine suppression of thyroid-stimulating hormone. The effectivity of the iodine-131 therepy were well accepted, but still some of issues were still debatable.
- Thyroid neoplasms /
- Iodine radioisotopes /
- Brachytherapy
本作品遵循Signature-Non-Commercial Use 4.0 International (CC BY-NC 4.0)协议

[1]	Grodski S, Delbridge L. An update on papillary microearcinoma. Curr Opin Oncol, 2009, 21(1):1-4.
[2]	Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med, 1994, 97(5):418-428.
[3]	Hay ID, Thompson GB, Grant CS, et al. Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999):temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg, 2002, 26(8):879-885.
[4]	Sawka AM, Thephamongkhol K, Brouwers M, et al. Clinical review 170:A systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer.J Clin Endocrinol Metab, 2004, 89(8):3668-3676.
[5]	Cooper DS, Doherty GM, Haugen BR, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer, Thyroid, 2006, 16(2):109-142.
[6]	Ma C, Kuang A, Xie J. Radioiodine therapy for differentiated thyroid carcinoma with thyroglobulin positive and radioactive iodine negative metastases. Cochrane Database Syst Rev, 2009, (1):CD006988.
[7]	Pluijmen MJ, Eustatia-Rutten C, Goslings BM, et al. Effects of lowiodide diet on postsurgical radioiodide ablation therapy in patients with differentiated thyroid carcinoma. Clin Endocrinol (Oxf), 2003,58(4):428-435.
[8]	Leger FA, Izembart M, Dagousset F, et al. Decreased uptake of therapeutic doses of iodine-131 after 185-MBq iodine-131 diagnostic imaging for thyroid remnants in differentiated thyroid carcinoma. Eur J Nucl Med, 1998, 25(3):242-246.
[9]	Park HM, Park YH, Zhou XH. Detection of thyroid remnant/metastasis without stunning:an ongoing dilemma. Thyroid, 1997, 7(2):277-280.
[10]	Edmonds C J, Hayes S, Kermode JC, et al. Measurement of serum TSH and thyroid hormones in the management of treatment of thyroid carcinoma with radioiodine. Br J Radiol, 1977, 50(599):799-807.
[11]	Torres MS, Ramirez L, Simkin PH, et al. Effect of various doses of recombinant human thyrotropin on the thyroid radioactive iodine uptake and serum levels of thyroid hormones and thyroglobulin in nurmal subjects.J Clin Endocrinol Metab, 2001, 86(4):1660-1664.
[12]	Robbins RJ, Schlumberger MJ. The evolving role of ¹³¹I for the treatment of differentiated thyroid carcinoma. J Nucl Med, 2005, 46(Suppl 1):28S-37S.
[13]	de Klerk JM, de Keizer B, Zelissen PM. Fixed dosage of ¹³¹I for remnant ablation in patients with differentiated thyroid carcinoma without pre-ablative diagnostic ¹³¹I scintigraphy. Nucl Med Commun, 2000, 21(6):529-532.
[14]	Tuttle RM, Leboeuf R, Robbins RJ, et al. Empiric:radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer. J Nucl Med, 2006, 47(10):1587-1591.
[15]	Van Nostrand D, Wartofsky L. Radioiodine in the treatment of thyroid cancer. Endocrinol Metab Clin North Am, 2007, 36(3):807-822.
[16]	Maxon HR 3rd, Englaro EE, Thomas SR, et al. Radioiodine-131 therapy for well-differentiated thyroid cancer-a quantitative radiation dosimetric approach:outcome and validation in 85 patients. J Nucl Med, 1992, 33(6):1132-1136.
[17]	Souza Rosário PW, Barroso AL, Rezende LL, et al. Post I-131 therapy scanning in patients with thyroid carcinoma metastases:an unnecessary cost or a relevant contribution?. Clin Nucl Med, 2004, 29(12):795-798.
[18]	Fatourechi V, Hay ID, Mullan BP. Are posttherapy radioiodine scans informative and do they influence subsequent therapy of patients with difterentiated thyroid cancer?. Thyroid, 2000, 10(7):573-577.
[19]	Sherman SI, Tielens ET, Sostre S. Clinical utility of posttreatment radioiodine scans in the management of patients with thyroid carcinoma. J Clin Endocrinol Metab, 1994, 78(3):629-634.
[20]	McGriff NJ, Csako G, Gourgiotis L, et al. Effects of thyroid hormone suppression therapy on adverse clinical outeomes in thyroid cancer. Ann Med, 2002, 34(7-8):554-564.
[21]	Kloos RT, Mazzaferri EL. A single recombinant human thyrotropinstimulated serum thyroglobulin measurement predicts differentiated thyroid carcinoma metastases three to five years later. J Clin Endocrinol Metab, 2005, 90(9):5047-5057.
[22]	Castagna MG, Brilli L, Pilli T, et al. Limited value of repeat recombinant human thyrotropin (rhTSH)-stimulated thyroglobulin testing in differentiated thyroid carcinoma patients with previous negative rhTSH-stimulated thyroglobulin and undetectable basal serum thyroglobulin levels. J Clin Endocrinol Metab, 2008, 93(1):76-81.
[23]	Eustatia-Rutten CF, Smit JW, Romijn JA, et al. Diagnostic value of serum thyroglobulin measurements in the follow-up of differentiated thyroid carcinoma, a structured meta-analysis. Clin Endocrinol (Oxf), 2004, 61(1):61-74.
[24]	Chung JK, Park YJ, Kim TY, et al. Clinical significance of elevated level of serum antithyroglobulin antibody in patients with differentiated thyroid cancer after thyroid ablation. Clin Endocrinol (Oxf), 2002, 57(2):215-221.

[1]	陈志军 , 谭丽玲 , 王文俊 , 周爱清 . ¹³¹I联合¹²⁵I粒子治疗难治性甲状腺癌骨转移一例. 国际放射医学核医学杂志, 2017, 41(1): 76-78. doi: 10.3760/cma.j.issn.1673-4114.2017.01.015
[2]	陈永辉 . 青少年分化型甲状腺癌与¹³¹I治疗. 国际放射医学核医学杂志, 2008, 32(6): 354-356.
[3]	李艳玲 , 栾兆生 . 维甲酸在¹³¹I治疗分化型甲状腺癌中的应用. 国际放射医学核医学杂志, 2009, 33(4): 226-228. doi: 10.3760/cma.j.issn.1673-4114.2009.04.010
[4]	董峰 , 周荫保 . 分化型甲状腺癌术后¹³¹I清甲效果的影响因素. 国际放射医学核医学杂志, 2010, 34(1): 27-31. doi: 10.3760/cma.j.issn.1673-4114.2010.01.007
[5]	张璐 , 詹维伟 , 张一帆 . 颈部超声在分化型甲状腺癌¹³¹I治疗中的应用进展. 国际放射医学核医学杂志, 2014, 38(4): 271-274. doi: 10.3760/cma.j.issn.1673-4114.2014.04.015
[6]	易婉婉 , 袁雪宇 , 蔡海东 , 刘瑾 , 张倩 , 范素云 , 吕中伟 . ¹³¹I治疗分化型甲状腺癌术后患者辐射剂量预测模型的研究. 国际放射医学核医学杂志, 2022, 46(2): 67-72. doi: 10.3760/cma.j.cn121381-202102004-00139
[7]	成钊汀 , 谭建 . 分化型甲状腺癌术后患者¹³¹I治疗的辐射剂量与防护. 国际放射医学核医学杂志, 2014, 38(2): 110-116. doi: 10.3760/cma.j.issn.1673-4114.2014.02.010
[8]	李永军 , 徐兆强 , 柳卫 , 程旭 , 包丽华 . 分化型甲状腺癌术后¹³¹I治疗患者胸腺生理性摄取¹³¹I的临床研究. 国际放射医学核医学杂志, 2014, 38(4): 227-231. doi: 10.3760/cma.j.issn.1673-4114.2014.04.005
[9]	郭睿 , 李彪 . 钠碘同向转运体基因介导放射性碘治疗肿瘤的研究进展. 国际放射医学核医学杂志, 2010, 34(3): 147-151. doi: 10.3760/cma.j.issn.1673-4114.2010.03.005
[10]	刘建宇 , 朱宗平 , 石德道 , 郑飞波 . 放射性碘难治性分化型甲状腺癌去分化分子机制及再分化治疗的分子靶向药物. 国际放射医学核医学杂志, 2023, 47(2): 123-126. doi: 10.3760/cma.j.cn121381-202205003-00267